Olink Holding Ab Publ Revenue Growth Rates (OLK), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Olink Holding Ab publ   (NASDAQ: OLK)
 

OLK's Revenue Growth by Quarter and Year

Olink Holding Ab Publ 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

OLK Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December 169.46
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 169.46





OLK Revenue fourth quarter 2023 Y/Y Growth Comment
Olink Holding Ab publ reported Revenue improvement of 21.17% year on year in the fourth quarter 2023, to $ 169.46 millions, this is lower than Olink Holding Ab Publ 's recent average Revenue improvement of 34.21%.

Looking into fourth quarter 2023 results within Laboratory Analytical Instruments industry 6 other companies have achieved higher Revenue growth. While Olink Holding Ab Publ ' s Revenue rise of 21.17% ranks overall at the positon no. 864 in the fourth quarter 2023.


OLK Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December 21.17 % 47.26 % - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   21.17 % 47.26 % - -

Financial Statements
Olink Holding Ab Publ 's fourth quarter 2023 Revenue $ 169.46 millions OLK's Income Statement
Olink Holding Ab Publ 's fourth quarter 2022 Revenue $ 139.85 millions Quarterly OLK's Income Statement


OLK Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   21.17 % 47.26 % - -


Back to OLK Growth rate Comparisons >> Back to OLK Growth rate Comparisons >>


Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #7
Healthcare Sector #213
Overall #864

Revenue Y/Y Growth Statistics
High Average Low
47.25 % 34.21 % 21.18 %
(Dec 31 2022)  
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #7
Healthcare Sector #213
Overall #864
Revenue Y/Y Growth Statistics
High Average Low
47.25 % 34.21 % 21.18 %
(Dec 31 2022)  

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Olink Holding Ab Publ 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


OLK's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


OLK's IV. Quarter Q/Q Revenue Comment


Olink Holding Ab Publ 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
 12 Months Ending
 12 Months Ending
Cumulative Revenue 12 Months Ending $ 169.46 $ 139.85 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) 21.18 % 47.25 % - - -
Year on Year Revenue Growth Overall Ranking # 352 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 21.18 % 47.25 % - - -
Seq. Revenue Growth (TTM) Overall Ranking # 352 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2023 period, Olink Holding Ab Publ 's cumulative twelve months Revenue were $ 169 millions, company would post below average annual Revenue growth of 47.25% year on year, if the fiscal year would end at Dec 31 2023.
A slow-down in the Olink Holding Ab Publ 's Revenue growth from the 0% growth in Dec 31 2022.

In the Healthcare sector 101 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 352.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 3
Healthcare Sector # 102
Overall # 352

Revenue TTM Y/Y Growth Statistics
High Average Low
47.25 %
 34.21 %
21.18 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 3
Sector # 102
S&P 500 # 352
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2023 period, Olink Holding Ab Publ 's cumulative twelve months Revenue were $ 169 millions, company would post below average annual Revenue growth of 21.18% year on year, if the fiscal year would end at Dec 31 2023.
A slow-down in the Olink Holding Ab Publ 's Revenue growth from the 0% growth in Dec 31 2022.

In the Healthcare sector 101 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 352.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 3
Healthcare Sector # 102
Overall # 352

Revenue TTM Y/Y Growth Statistics
High Average Low
47.25 %
34.21 %
21.18 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 3
Sector # 102
S&P 500 # 352




Other Revenue Growth
Laboratory Analytical Instruments Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
OLK's Revenue Growth Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2023
Zomedica Corp 36.85%$ 36.852 millions
Viemed Healthcare Inc 35.28%$ 35.275 millions
Kiniksa Pharmaceuticals International Plc34.76%$ 34.760 millions
Omega Therapeutics Inc 34.60%$ 34.605 millions
Lantheus Holdings Inc 34.56%$ 34.557 millions
P3 Health Partners Inc 34.33%$ 34.332 millions
Nephros Inc 34.28%$ 34.285 millions
Xeris Biopharma Holdings Inc 33.93%$ 33.931 millions
Eyepoint Inc 33.18%$ 33.181 millions
Deciphera Pharmaceuticals Inc 32.88%$ 32.877 millions
Anaptysbio Inc 32.27%$ 32.271 millions
Amphastar Pharmaceuticals Inc 31.91%$ 31.907 millions
Twist Bioscience Corporation31.81%$ 31.811 millions
Clearpoint Neuro Inc 31.62%$ 31.620 millions
Corcept Therapeutics Inc31.39%$ 31.390 millions
Harmony Biosciences Holdings inc 31.30%$ 31.303 millions
Alnylam Pharmaceuticals Inc 31.25%$ 31.245 millions
Dermtech Inc 31.06%$ 31.062 millions
Tarsus Pharmaceuticals Inc 30.76%$ 30.760 millions
Alphatec Holdings Inc 30.73%$ 30.734 millions
Amicus Therapeutics inc 30.63%$ 30.632 millions
Thermogenesis Holdings Inc 30.61%$ 30.605 millions
Bionano Genomics Inc 30.51%$ 30.505 millions
Conmed Corporation30.37%$ 30.366 millions
Schrodinger Inc 30.33%$ 30.327 millions
Immucell Corporation30.30%$ 30.303 millions
Urogen Pharma Ltd 30.06%$ 30.057 millions
Quanterix Corporation29.25%$ 29.248 millions
Onemednet Corporation29.18%$ 29.179 millions
Pulmatrix Inc 28.92%$ 28.923 millions


About Olink Holding Ab Publ Revenue Growth Rates (OLK), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Olink Holding Ab publ (CIK 1835539).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-24-012810
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Olink Holding Ab publ ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.